Since closing a major funding round backed by prominent Chinese investors last year, ZXBio (Yang Zhang ’19) has continued to build momentum. The company just reached a pivotal milestone in its mission to make high-quality diagnostics more accessible in China.
ZXBio recently received two Class III medical device registration certificates from China’s National Medical Products Administration (NMPA), the country’s top regulatory body for medical devices. The approved products are flow cytometry kits that analyze immune cell composition in a patient’s blood, providing clinicians with critical information for diagnosing and monitoring tumors, autoimmune diseases, and infectious diseases. Class III is the most stringent certification category under NMPA, reserved for products that carry the highest clinical significance – making this approval a substantial regulatory achievement.
For founder and Yale SOM alumnus Yang Zhang ’19, the milestone is deeply personal. “This is a breakthrough in the field in China,†Zhang said. ZXBio is now the first company in Huzhou City to hold Class III registrations for this category of diagnostic kits, a distinction that carries commercial as well as symbolic weight: until now, the Chinese market for these products has been dominated by imported goods. ZXBio’s domestically developed kits offer a high-quality alternative, directly advancing the company’s founding goal of reducing Chinese patients’ reliance on expensive foreign medical products.
The approval also validates years of scientific work rooted in Zhang’s academic background. Holding a Ph.D. in Immunology from UCSF, Zhang built ZXBio around proprietary monoclonal antibody technology developed during his research career. The company now holds nearly 50 patents and over 140 Chinese medical device filings and registrations.
ZXBio has also earned recognition beyond its home city: in 2025, the company was named to the “IVD Innovation Top 100†list and selected as a “Deloitte China Pharma & Healthcare Rising Star.†With regulatory approval now secured for two flagship diagnostic products, ZXBio is well-positioned to scale its commercial footprint and continue delivering on its promise to provide precision care for Chinese patients.
Read more about ZXBio and Zhang’s journey.
